1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


TABLE 1: 
Analysis of significant differences between tumor groups at TE 30
Pairwise ComparisonsResonances Showing Significant Differences†
P* < .001P* < .01P* < .05
MEN vs LGAGLXAlaGly/MI
MEN vs AAAlaCR
MEN vs GBM-METLIP09, LIP13, Ala, GLX, CR, CHO, Gly/MI
LGA vs AA
LGA vs GBM-METLIP09, LIP13, CR, Gly/MI
AA vs GBM-METLIP13, CR, CHOLIP09, Gly/MI
  • Note.—Differences of P corrected values (P*) <.05 were considered to be statistically significant. MEN indicates meningioma; LGA, low grade astrocytoma; AA, anaplastic astrocytoma; GBM-MET, glioblastoma-metastasis group; GLX, glutamate and glutamine; Ala, alanine; LIP, lipid; CR, creatine plus phosphocreatine; CHO, choline and other thmethylamine-containing compounds; Gly/MI, glycine and/or myo-inositol.
  • † Only the seven resonances showing significant differences in the previously applied Kruskal-Wallis test for multiple samples were considered (LIP09, LIP13, Ala, GLX, CR, CHO, and Gly/MI).